RxDoctor Payments Data

Justin Amador

Family · Los Angeles, CANPI 1760772321

Payments from drug & device makers

$2,626in general payments, 2019–2025

Across 107 payments — averaging $24.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$1K
  • Viiv Healthcare Company$703
  • Alkermes, Inc.$211
  • AbbVie$188
  • Organon$82
  • EMD Serono, Inc.$50
  • plus $154 from 5 others

What the payments were for

  • Food & beverage$2,626100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,626 in reported general payments places this provider in the 85th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$3,925
Medicare patients
14
Services billed
76

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpclusaSofosbuvir/Velpatasvir20$459,179
GenvoyaElviteg/Cob/Emtri/Tenof Alafen41$163,040
JulucaDolutegravir/Rilpivirine26$86,238
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf15$76,493
DescovyEmtricitabine/Tenofov Alafenam20$60,986
BiktarvyBictegrav/Emtricit/Tenofov Ala13$50,281
TriumeqAbacavir/Dolutegravir/Lamivudi11$38,259
SuboxoneBuprenorphine Hcl/Naloxone Hcl12$9,756
Estradiol (Twice Weekly)Estradiol26$2,051
Estradiol45$1,352
Tamsulosin Hcl33$341
Spironolactone31$338
Albuterol Sulfate HfaAlbuterol Sulfate14$327
Gabapentin19$318
Atorvastatin Calcium23$259

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadEpclusa, Genvoya, Descovy, Biktarvy$1,238$733,48594 claims
Viiv Healthcare CompanyJuluca, Triumeq$703$124,49837 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,634 family providers in California.

Other family in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →